Great Point Partners LLC Xenon Pharmaceuticals Inc. Transaction History

Great Point Partners LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$42.66 - $50.04 $6.14 Million - $7.2 Million	-143,852 Reduced 23.98%	456,148 $19.6 Million
Q4 2023 Feb 14, 2024	BUY	$28.7 - $46.46 $2.87 Million - $4.65 Million	99,999 Added 20.0%	600,000 $27.6 Million
Q3 2023 Nov 14, 2023	SELL	$34.16 - $39.73 $1.02 Million - $1.19 Million	-29,999 Reduced 5.66%	500,001 $17.1 Million
Q2 2023 Aug 14, 2023	SELL	$34.84 - $43.54 $10.1 Million - $12.6 Million	-288,505 Reduced 35.25%	530,000 $20.4 Million
Q1 2023 May 15, 2023	SELL	$33.46 - $40.35 $1.05 Million - $1.27 Million	-31,495 Reduced 3.71%	818,505 $29.3 Million
Q3 2022 Nov 14, 2022	SELL	$30.79 - $39.82 $7.83 Million - $10.1 Million	-254,334 Reduced 23.03%	850,000 $30.7 Million
Q2 2022 Aug 15, 2022	BUY	$25.44 - $35.16 $4.69 Million - $6.48 Million	184,334 Added 20.04%	1,104,334 $33.6 Million
Q1 2022 May 16, 2022	SELL	$25.09 - $33.13 $752,700 - $993,900	-30,000 Reduced 3.16%	920,000 $28.1 Million
Q4 2021 Feb 14, 2022	BUY	$15.6 - $35.4 $3.9 Million - $8.85 Million	250,000 Added 35.71%	950,000 $29.7 Million
Q3 2021 Nov 15, 2021	BUY	$14.86 - $19.45 $10.4 Million - $13.6 Million	700,000 New	700,000 $10.7 Million

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.42B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.